What is Acute myelogenous leukemia (AML)

Acute myelogenous leukemia (AML) is a type of cancer that affects the bone marrow and blood. It is characterized by the rapid growth of abnormal white blood cells, which are responsible for fighting infections in the body. AML starts in the bone marrow, where blood cells are produced, and quickly spreads to the bloodstream and other parts of the body.

AML is a serious condition that can progress rapidly if left untreated. Common symptoms include fatigue, frequent infections, easy bruising or bleeding, and shortness of breath. The exact cause of AML is often unknown, but certain risk factors such as exposure to radiation or certain chemicals, previous chemotherapy or radiation therapy, and certain genetic disorders can increase the likelihood of developing the disease.

Diagnosis of AML involves blood tests, bone marrow biopsy, and imaging tests to determine the extent of the disease. Treatment options for AML include chemotherapy, radiation therapy, targeted therapy, and stem cell transplantation. The choice of treatment depends on various factors, including the patient's age, overall health, and specific genetic mutations.

Early detection and prompt treatment are crucial for improving outcomes in AML. Ongoing research and advancements in treatment options offer hope for better prognosis and quality of life for individuals affected by this disease.